Patent classifications
A61M1/3479
GASLESS EXTRA-CORPOREAL CARBON DIOXIDE REMOVAL
A carbon dioxide absorption medium. The absorption medium includes a plurality of hollow fibers and a plurality of binder particles. The hollow fibers have walls comprising a selectively permeable membrane that is configured to permit passage of gaseous carbon dioxide but not liquids. The plurality bind particles are dispersed between the hollow fibers and comprise an absorbent material configured to absorb gaseous carbon dioxide and to bind the carbon dioxide in a solid state.
Hemodialyzer for blood purification
The present disclosure relates to a dialyzer comprising a bundle of semipermeable hollow fiber membranes which is suitable for blood purification, wherein the dialyzer has an increased ability to remove larger molecules while at the same time it is able to effectively remove small uremic toxins and efficiently retain albumin and larger proteins. The invention also relates to using said dialyzer in hemodialysis.
Wearable Ultrafiltration Devices Methods and Systems
A wearable ultrafiltration apparatus is provided. The apparatus can include a first ultrafilter for filtering a patient's blood along a first fluid path and a second ultrafilter for filtering the patient's blood along a second fluid path. The apparatus can also include a valve being positionable in a first position for directing the patient's blood along the first fluid path. The valve can also be positioned in a second position for directing the patient's blood along the second fluid path. When the valve is in the first position, blood can flow along the first fluid path and prevent blood from flowing along the second fluid path. When the valve is in the second position, blood can flow along the second fluid path and prevent blood from flowing along the first fluid path. When the valve is in the first position, the second ultrafilter can be idle and capable of being serviced or replaced and when the valve is in the second position, the first ultrafilter can be idle and capable of being serviced or replaced. Therefore, when a ultrafilter fouls, blood can be directed to the other ultrafilter while the fouled ultrafilter is being serviced or replaced.
APHERESIS TO REDUCE HIGH BLOOD PRESSURE IN PRE-ECLAMPSIA
There are certain factors in the blood of pregnant women with pre-eclampsia that appear to be associated with the disease. These include a soluble variant of the fms-like tyrosine kinase receptor (sFlt-1), soluble Endoglin (sEndoglin), and Endothelin-1. There is also evidence that hypertension may be caused by Na/K ATPase inhibitors such as digitalis-like factor, ouabain-like factors, marinobufogenin and marinobufotoxin. This invention teaches the removal of multiple harmful factors using a combination of targeted apheresis and dialysis and/or ultrafiltration. Harmful factors that are proteins are bound out using immobilized binding agents such as antibodies, aptamers and binding peptides, while small molecule harmful factors are dialyzed out or filtered out. Removal of multiple harmful factors is expected to ameliorate the symptoms of pre-eclampsia and prolong pregnancy.
DEVICE AND METHOD FOR THE PREPARATION OF PLATELET RICH PLASMA
The present invention relates to a device and method for the preparation of platelet rich plasma, and to the plasma obtained by employing said device and method. The method comprises evaporating and dialysing plasma with the device of the invention to provide a plasma enriched in platelets and non-platelet biomolecules. The plasma thus obtained shows improved regenerative properties with respect to other plasma preparations.
Regional ant-coagulation system for an extracorporeal circulation circuit
The present invention concerns an extracorporeal circuit for regional scoagulation of blood comprising a line for taking the blood from the patient, a first filtering unit, and a line for returning the blood to the patient defining a main circuit, the extracorporeal circuit comprising a secondary circuit for recirculation of the plasma water comprising: a calcium removal assembly adapted to provide a solution with low calcium content in said main circuit;
the extracorporeal circuit further comprising: first means for the infusion of said solution with low calcium content into said main circuit upstream of said first filtering unit and of said calcium removal assembly with respect to the blood flow direction in the main circuit and second means for the infusion of an electrolytic re-establishment solution located downstream of said first means with respect to the direction of the blood flow in said main circuit.
Extracorporeal device and method for removal of secondary membrane
An extracorporeal blood treatment device and a method are provided for removing a secondary membrane formed on a semipermeable membrane of a dialyzer during an extracorporeal blood treatment. The extracorporeal blood treatment device operates in a first operating mode in which a dialysate outlet valve is open such that dialysate flows through a dialyzer feed line, through a dialysate chamber, and into and through a dialyzer discharge line. The extracorporeal blood treatment device operates in a second operating mode to remove the secondary membrane from the semipermeable membrane. During the second operating mode, the dialysate outlet valve is closed for a duration of time such that dialysate is prevented from flowing through the dialyzer discharge line. A backflush procedure results wherein a volume of dialysate passes from the dialysate chamber through the semipermeable membrane and into the blood chamber.
Wearable ultrafiltration devices methods and systems
A wearable ultrafiltration apparatus is provided. The apparatus can include a first ultrafilter for filtering a patient's blood along a first fluid path and a second ultrafilter for filtering the patient's blood along a second fluid path. The apparatus can also include a valve being positionable in a first position for directing the patient's blood along the first fluid path. The valve can also be positioned in a second position for directing the patient's blood along the second fluid path. When the valve is in the first position, blood can flow along the first fluid path and prevent blood from flowing along the second fluid path. When the valve is in the second position, blood can flow along the second fluid path and prevent blood from flowing along the first fluid path. When the valve is in the first position, the second ultrafilter can be idle and capable of being serviced or replaced and when the valve is in the second position, the first ultrafilter can be idle and capable of being serviced or replaced. Therefore, when a ultrafilter fouls, blood can be directed to the other ultrafilter while the fouled ultrafilter is being serviced or replaced.
Extracorporeal circuit for CO2 removal from blood
The present invention relates to an extracorporeal circuit for CO.sub.2 removal from blood comprising a line for taking blood from the patient, a decarboxylation assembly and a line for returning the blood to the patient; said decarboxylation assembly comprising a first filtering unit, an oxygenator, an electrodialyzer adapted to generate an acid solution and a basic solution and means for the infusion of said acid solution upstream of said oxygenator, wherein said electrodialyzer comprises a first electrodialysis chamber and a second electrodialysis chamber, said first and second electrodialysis chambers being separated by an ionic membrane, and wherein said first chamber and said second chamber are respectively separated from the positive electrode, or anode, and from the negative electrode, or cathode, by means of a bipolar membrane.
EXTRACORPOREAL DEVICES AND METHODS OF TREATING COMPLEMENT FACTOR RELATED DISEASES
The present disclosure relates to devices for the extracorporeal treatment of a patient having a complement factor related disease. The devices are adapted to remove said complement factors from the blood or blood plasma of a patient in need. The disclosure further relates to extracorporeal circuits comprising such devices and methods for the treatment of a patient suffering from a complement factor related disease.